News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1Bitcoin back to record fear levels as it wipes weekend gains2The Funding: Why TradFi giants like BlackRock are buying DeFi tokens now3Will Solana fall another 95%? Why SOL’s bottom looks far away
Celo (CELO) Price Prediction 2026, 2027-2030: Is Now the Best Time to Accumulate CELO?
Coinpedia·2026/02/23 12:30
How Bitcoin Mining in Iran Can Cost Just $1,320 and Sell for $68,000
Coinpedia·2026/02/23 12:30
SEC ETF Deadline, CLARITY Act, New Fed Chair: 5 Events That Will Define Crypto in 2026
Coinpedia·2026/02/23 12:30
Alchemy Pay Launches Public Testnet for Payment-Focused Blockchain
Cointurk·2026/02/23 12:21
Trump Rips Into Taiwan After Supreme Court Tariff Blow
Finviz·2026/02/23 12:12
US to make tariff decision on solar panels from India, Indonesia and Laos
101 finance·2026/02/23 12:12
Are financial experts on Wall Street optimistic about United Rentals shares?
101 finance·2026/02/23 12:12
Exclusive: Reliance Global Completes Enquantum Deal, Starts Path To 51% Ownership
Finviz·2026/02/23 12:09
Itron Announces $600.0 Million Convertible Senior Notes
Finviz·2026/02/23 12:03
Flash
12:27
ADC Therapeutics SA (ADCT) recently released its performance outlook, expecting the company to enter a substantial growth phase starting in 2027.According to analysis, its potential annual revenue peak in the US market is expected to reach between $600 million and $1 billion. This optimistic outlook is based on the commercialization progress of the company's core product pipeline and its market expansion strategy. As innovative therapies gradually receive regulatory approval and expand their indications, ADC Therapeutics is expected to capture a significant market share in the field of oncology treatment. The company's management emphasized that this growth trajectory depends on the smooth execution of clinical development plans and the effective implementation of market penetration strategies. If all progresses as expected, the company's financial performance will see a significant improvement after 2027.
12:27
Healthcare Royalty Partners granted warrants to purchase approximately 9.8 million ordinary shares to ADC Therapeutics SA.According to the terms of the agreement, the exercise price for each warrant is set at $3.81 per share. The granting of these warrants will provide ADC Therapeutics SA with a potential capital injection, while also offering investors the right to purchase the company's common shares at a fixed price in the future.
12:26
ADC Therapeutics SA announced that, in the event of a change of control, the acquirer will continue to pay royalties to the healthcare royalty company until the originally agreed cap amount is reached.This arrangement ensures the continuity of concession revenues, unaffected by changes in the company's ownership structure.
News